Cambridge rare disease biotech Synageva to be acquired for $8.4B

May 6, 2015 11:01 AM

49 0

Cambridge rare disease biotech Synageva to be acquired for $8.4B

Cambridge rare disease biotech Synageva BioPharma Corp. will be acquired for $8.4 billion by Connecticut-based Alexion Pharmaceuticals, the two companies announced today.

Alexion (Nasdaq: ALXN) has agreed to pay a per-share price of $230, more than double the $95 price as of yesterday’s close for Synageva (Nasdaq: GEVA).

Also read: Court: Firms have duty to protect households from asbestos

Read more

To category page

Loading...